Screener / SEC EDGAR /CIK 0000885725 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Instruments

Boston Scientific BSX

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. 10-K, Item 1

Employees
59,000
Headquarters
Marlborough, MA
CEO
Michael F. Mahoney
Next results
around Feb 3, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $20.1B through the costs to a net profit of $2.9B · income statement of the 10-K

18% operating margin
Revenue to Gross profit: $13.9BRevenue to Cost of revenue: $6.2BGross profit to Operating profit: $3.6BGross profit to Operating expenses: $10.2BOperating profit to Net profit: $2.9BOperating profit to Tax & other: $715.0MOperating expenses to R&D: $2.1BOperating expenses to Sales, admin & other: $8.2B Revenue: $20.1B REVENUE $20.1B +20% Y/Y Gross profit: $13.9B · 69% margin GROSS PROFIT $13.9B 69% margin · +21% Y/Y Cost of revenue: $6.2B · 31% of revenue COST OF REVENUE $6.2B 31% of revenue Operating profit: $3.6B · 18% margin OPERATING PROFIT $3.6B 18% margin · +39% Y/Y Operating expenses: $10.2B · 51% of revenue OPERATING EXPENSES $10.2B 51% of revenue Net profit: $2.9B · 14% margin NET PROFIT $2.9B 14% margin · +56% Y/Y Tax & other: $715.0M · 4% of revenue TAX & OTHER $715.0M 4% of revenue R&D: $2.1B · 10% of revenue R&D $2.1B 10% of revenue Sales, admin & other: $8.2B · 41% of revenue SALES, ADMIN & OTHER $8.2B 41% of revenue
Gross profit $13.9B 69% margin · +21% Y/Y
Operating profit $3.6B 18% margin · +39% Y/Y
Net profit $2.9B 14% margin · +56% Y/Y
The full income statement, year by year

BSX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 19.9%, above 93% of 59 peers (their median 7.1%) REVENUE GROWTH 19.9% · above 93% Gross margin: 69.1%, above 66% of 50 peers (their median 64.2%) GROSS MARGIN 69.1% · above 66% Operating margin: 18.7%, above 66% of 50 peers (their median 13.4%) OPERATING MARGIN 18.7% · above 66% Net margin: 16.6%, above 73% of 59 peers (their median 9.5%) NET MARGIN 16.6% · above 73% FCF margin: 15.8%, above 51% of 55 peers (their median 15.2%) FCF MARGIN 15.8% · above 51% Return on capital: 8.2%, above 39% of 41 peers (their median 9.2%) RETURN ON CAPITAL 8.2% · above 39%
BSX Peer median Below the median

What changed

3 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 17, 2026 against Feb 18, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Valuation of intangible assets acquired in business combinations (“As disclosed in Note B to the consolidated financial statements, during 2025, the Company completed the acquisitions of Bolt Medical, Inc. and SoniVie Ltd. for purchase prices, net of cash acquired, of $782 million and $516 million, respectively.”)
  • Receivables +14.4% vs revenue +19.9% (-5.5 pts)
9 more checks with nothing to note
  • Cash from operations $4.5B vs net income $2.9B (FY ending Dec 31, 2025)
  • Inventory +4.7% vs revenue +19.9% (-15.1 pts)
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

3 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.

All 3 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    Our business and operations are subject to risks related to natural disasters, climate change and other extreme weather.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    We are subject to certain U.S. tariffs that are currently subject to legal challenge before the U.S. Supreme Court. The timing and outcome of this litigation are uncertain, and the Court’s decision could result in the modification, invalidation, or continuation of such tariffs. Any modification of existing tariffs, or the introduction…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$12.7B$14.2B$16.7B$20.1B
Net income$642.0M$1.6B$1.9B$2.9B
Operating cash flow$1.5B$2.5B$3.4B$4.5B
Free cash flow$938.0M$1.8B$2.6B$3.7B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$20.1B ▲ 19.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Boston Scientific, Marlborough, MA · from the 10-K filed Feb 17, 2026

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.

Headquarters
Marlborough, MA
Country
United States
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 28, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had approximately 59,000 employees, of which approximately 60 percent were outside the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BSX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.